Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

Encenicline is a novel, selective α7 nicotinic acetylcholine receptor agonist in development for treating cognitive impairment in schizophrenia and Alzheimer's disease. A phase 2, double-blind, randomized, placebo-controlled, parallel-design, multinational study was conducted. Patients with sch...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuropsychopharmacology
Glavni autori: Keefe, Richard SE, Meltzer, Herbert A, Dgetluck, Nancy, Gawryl, Maria, Koenig, Gerhard, Moebius, Hans J, Lombardo, Ilise, Hilt, Dana C
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2015
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4864641/
https://ncbi.nlm.nih.gov/pubmed/26089183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2015.176
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items